Patent · US Active

(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors

US9469597B2 · kind B2 · utility

7Cited by

19References

14Claims

0Family size

Assignee

Oryzon Genomics S.A. · ES

Inventors

Alberto Ortega Muñoz · Barcelona, ES
Matthew Colin Thor Fyfe · Chipping Norton, GB
Marc Martinell Pedemonte · Barcelona, ES
Maria de los Àngeles Estiarte Martinez · San Francisco, US
Nuria Valls Vidal · Barcelona, ES
Guido Kurz · Barcelona, ES
Julio Cesar Castro Palomino Laria · Premià de Mar, ES

Key dates

Filing date	Oct 22, 2012
Grant date	Oct 18, 2016
Priority date	—
Expiry date	Oct 30, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C2602/08
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.